期刊文献+

CT抗原KM-HN-1 HLA-A*0201限制性表位预测及其与HLA-A*0201结合强度分析 被引量:2

Prediction of HLA-A*0201 restricted epitopes from a cancer-testis antigen KM-HN-1 and peptide HLA-A*0201 binding & complex stability assay of the candidate peptides
下载PDF
导出
摘要 目的通过对CT抗原(cancer-testis antigen)KM-HN-1进行HLA-A*0201限制性表位预测,并对候选表位肽与HLA-A*0201分子结合亲和力及复合物稳定性进行分析,为探索基于KM-HN-1的免疫治疗奠定基础。方法利用基于蛋白酶体剪切位点特异性的算法PAProc及基于肽MHC-I结合的算法BIMAS和SYFPEITHI对KM-HN-1进行HLA-A*0201限制性表位预测.合成KM-HN-1相关候选表位肽KM-HN-I321-329(KLLPFRETV),KM-HN-I303-211,(FLPTAPPNV),KM-HN-I629-637。(TLLQIIETV),KM-HN-I87-95(ILNKSIIEV),KM-HN-I538-596。(QMMEALDQL)及阳性对照肽HBVcAg18-27(FLPSDFFPSV);对这些合成肽与HIA-A*0201分子结合亲和力及其复合物稳定性根据文献报道的方法进行分析。结果KM-HN-I321-329(KLLPERETV)结合亲和力最低,KM-HN—I203-211(FLPTAPPNV)结合亲和力最高,其余3条肽结合亲和力介于2者之间;稳定性实验(DC50)结果显示:KM-HN-I538—546(QMMEALDQL)DC50小于2h,KM—HN-I321-329(KLLPERETV)的DC50介于2~4h之间,KM-HN-I87-95。(ILNKSIIEV)的DC50介于6~8h之间,KM-HN-I233-211(HLPTAPPNV)及KM-HN-I629—633(TLLQIIETV)的DC50均大于8h。结论基于蛋白酶体剪切位点特异性的算法及基于肽MHC-I结合的算法对KM-HN-1进行HLA-A*0201限制性表位预测,结合候选表位肽与HLA-A*0201分子结合的亲和力与复合物稳定性实验分析,为该抗原HLA-A*0201限制性表位的鉴定奠定了基础。 Objective To predict HLA-A *0201 restricted epitopes from cancer-testis (C-T) antigen KM-HN-1 and assay the HLA-A 0201 peptide binding & complex stability of the predicted epitopes for developing cancer therapeutic vaccine based on KM-HN-1. Methods Proteasomal cleavage specificity based and peptide-MHC-I binding based algorithms were combined to predict HLA-A* 0201 restricted epitopes from antigen KM-HN-1. Peptide-MHC-I binding was predicted using 2 algorithms: BIMAS and SYFPEITHI. Proteasomal cleavage specificity was predicted using algorithm PAProc. The peptides were ranked for each algorithm and sorted by a cumulative score. Five candidate epitope peptides [KM-HN-I321-329(KLLPFRETV), KM-HN-1203_2H (FLFFAPPNV), KM-HN-I629-637 (TLLQIIETV), KM-HN-I87-95 (ILNKSI- IEV), and KM-HN-I538-546 (QMMEALDQL)] and positive control peptide were synthesized. Peptide HIA-A * 0201 binding and complex stability was assayed following previously described methods. Results KM-HN-I321-329 (KLLPFRETV) showed the lowest HLA-A * 0201 binding aflqnity among the 5 candidates, while KM-HN-I203-211 (FLFFAPPNV) was of the highest HLA-A * 0201 binding aflqnity and the rest of the peptides showed intermediate binding aflqnity. The complex stability assay indicated that the dissociation complex 50 (DC50) for KM-HN-I538-546 (QMMEALDQL) was below 2 h, the DC50 for KM-HN-I32-329 (KLLPFRETV) was 2 - 6 h, the DC50. for KM-HN-I87-95 (ILNKSIIEV) was 6 - 8 h, and the DC50 for KM-HN-I203-211(FLFFAPPNV) and KM-HN-I629-637 (TLLQIIETV) were both above 8 h. Conclusion The prediction of HLA-A * 0201 restricted epitopes from CF antigen KM-HN-1 and the peptide HLA-A * 0201 binding aflqnity & complex stability assay of the 5 candidate peptides provide experimental data for identification of HLA-A * 0201 restricted epitopes from KM-HN-1.
出处 《免疫学杂志》 CAS CSCD 北大核心 2006年第6期593-596,共4页 Immunological Journal
基金 国家重点基础研究发展规划"973"项目(2003CB514108) 国家自然科学基金面上项目(30300315)资助
关键词 CT抗原 KM-HN-1 表位预测 HLA-A*0201限制性 结合亲和力及稳定性 Cancer-testis antigen KM-HN-1 Epitope prediction HLA-A * 0201 restriction Binding aifinity & complex stability
  • 相关文献

参考文献15

  • 1van der Bruggen P,Traversari C,Chomez P,et al.A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma[J].Science,1991,254 (5 038):1 643-1 647.
  • 2Old LJ.Cancer/testis (CT) antigens-a new link between gametogenesis and cancer[J].Cancer Immun,2001,1:1-7.
  • 3Scanlan MJ,Gure AO,Jungbluth AA,et al.Cancer/testis antigens:an expanding family of targets for cancer immunotherapy[J].Immunol Rev,2002,188:22-32.
  • 4Monji M,Nakatsura T,Senjus Y,et al.Identification of a novel human cancer/testis antigen,KM-HN-I,recognized by cellular and humoral immune responses[J].Clin Cancer Res,2004,10(18 pt 1):6 047 -6 057.
  • 5Parker KC,Bednarek MA,Coligan JE,et al.Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains[J].J Immuno,1994,152(1):163-175.
  • 6Rammensee H,Bachmann J,Emmerich NP,et al.SYFPEITHI:database for MHC ligands and peptide motifs[J].Immunogenetics,1999,50(3/4):213-219.
  • 7Nussbaum AK,Kuttler C,Hadeler KP,et al.PAProC:a prediction algorithm for proteasomal cleavages available on the WWW[J].Immunogenetics,2001,53(2):87-94.
  • 8Passoni L,Scardino A,Bertazzoli C,et al.ALK as a novel lymphoma-associated tumor antigen:identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes[J].Blood,2002,99(6):2 100-2 106.
  • 9Tourdot S,Scardino A,Saloustrou E,et al.A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides:implication in the identification of cryptic tumor epitopes[J].Eur J Immunol,2000,30 (12):3 411-3 421.
  • 10Chen YT,Scanlan MJ,Venditti CA,et al.Identification of cancer/testis-antigen genes by massively parallel signature sequencing[J].Proc Natl Acad Sci USA,2005,102 (22):7 940-7 945.

同被引文献2

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部